Biodistribution and dosimetry of a single dose of albumin-binding ligand [¹⁷⁷Lu]Lu-PSMA-ALB-56 in patients with mCRPC.

ABSTRACT:

Introduction

PSMA-targeted radionuclide therapy with lutetium-177 has emerged as an effective treatment option for metastatic, castration-resistant prostate cancer (mCRPC). Recently, the concept of modifying PSMA radioligands with an albumin-binding entity was demonstrated as a promising measure to increase the tumor uptake in preclinical experiments. The aim of this study was to translate the concept to a clinical setting and evaluate the safety and dosimetry of [¹⁷⁷Lu]Lu-PSMA-ALB-56, a novel PSMA radioligand with albumin-binding properties.

Methods

Ten patients (71.8 ± 8.2 years) with mCRPC received an activity of 3360 ± 393 MBq (120-160 μg) [¹⁷⁷Lu]Lu-PSMA-ALB-56 followed by whole-body SPECT/CT imaging over 7 days. Volumes of interest were defined on

SUBMITTER: Kramer V 

PROVIDER: S-EPMC8036212 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature